Meilleure Health International Industry Group 将来の成長

Future 基準チェック /06

現在、 Meilleure Health International Industry Groupの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Trade Distributors 収益成長	6.5%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	None
最終更新日	n/a

今後の成長に関する最新情報

Recent updates

Meilleure Health International Industry Group's (HKG:2327) Shareholders May Want To Dig Deeper Than Statutory Profit

Oct 04

Earnings Not Telling The Story For Meilleure Health International Industry Group Limited (HKG:2327) After Shares Rise 34%

Sep 05

Meilleure Health International Industry Group (HKG:2327) Has A Somewhat Strained Balance Sheet

Aug 30

Meilleure Health International Industry Group Limited's (HKG:2327) 31% Share Price Plunge Could Signal Some Risk

Jul 19

Meilleure Health International Industry Group (HKG:2327) Will Be Hoping To Turn Its Returns On Capital Around

Jun 17

Optimistic Investors Push Meilleure Health International Industry Group Limited (HKG:2327) Shares Up 32% But Growth Is Lacking

May 03

Meilleure Health International Industry Group's (HKG:2327) Earnings Are Of Questionable Quality

Apr 04

Some Confidence Is Lacking In Meilleure Health International Industry Group Limited (HKG:2327) As Shares Slide 30%

Feb 28

Returns Are Gaining Momentum At Meilleure Health International Industry Group (HKG:2327)

Jan 23

Returns At Meilleure Health International Industry Group (HKG:2327) Appear To Be Weighed Down

Aug 17

Investors Met With Slowing Returns on Capital At Meilleure Health International Industry Group (HKG:2327)

Oct 18

Is Meilleure Health International Industry Group (HKG:2327) A Risky Investment?

Sep 06

Investors Will Want Meilleure Health International Industry Group's (HKG:2327) Growth In ROCE To Persist

Jul 12

Does Meilleure Health International Industry Group (HKG:2327) Have A Healthy Balance Sheet?

Sep 09

Meilleure Health International Industry Group (HKG:2327) Shareholders Will Want The ROCE Trajectory To Continue

May 15

Meilleure Health International Industry Group (HKG:2327) Seems To Use Debt Rather Sparingly

Apr 18

Did You Miss Meilleure Health International Industry Group's (HKG:2327) Impressive 124% Share Price Gain?

Jan 29

Here's What We Think About Meilleure Health International Industry Group's (HKG:2327) CEO Pay

Dec 08

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Meilleure Health International Industry Group は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

SEHK:2327 - アナリストの将来予測と過去の財務データ ( )HKD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2024	84	31	56	56	N/A
3/31/2024	107	36	-41	-40	N/A
12/31/2023	129	41	-137	-136	N/A
9/30/2023	130	33	-123	-122	N/A
6/30/2023	130	25	-109	-108	N/A
3/31/2023	125	22	-33	-32	N/A
12/31/2022	120	18	42	43	N/A
9/30/2022	148	23	42	46	N/A
6/30/2022	177	28	43	49	N/A
3/31/2022	215	44	-24	-17	N/A
12/31/2021	253	60	-90	-83	N/A
9/30/2021	263	72	-27	-24	N/A
6/30/2021	273	84	35	36	N/A
3/31/2021	269	84	53	53	N/A
12/31/2020	265	83	70	71	N/A
9/30/2020	262	32	11	11	N/A
6/30/2020	259	-19	-49	-48	N/A
3/31/2020	247	-19	-12	-12	N/A
12/31/2019	235	-20	25	25	N/A
9/30/2019	221	31	74	74	N/A
6/30/2019	208	83	123	123	N/A
3/31/2019	219	82	70	70	N/A
12/31/2018	231	81	18	18	N/A
9/30/2018	181	81	-40	-38	N/A
6/30/2018	132	81	-98	-94	N/A
3/31/2018	101	81	N/A	-79	N/A
12/31/2017	69	80	N/A	-63	N/A
9/30/2017	83	60	N/A	-177	N/A
6/30/2017	97	40	N/A	-291	N/A
3/31/2017	82	37	N/A	-276	N/A
12/31/2016	67	34	N/A	-261	N/A
12/31/2015	76	10	N/A	0	N/A
9/30/2015	17	-1	N/A	-45	N/A
6/30/2015	13	0	N/A	-21	N/A
3/31/2015	9	2	N/A	3	N/A
12/31/2014	16	1	N/A	29	N/A
9/30/2014	22	0	N/A	54	N/A
6/30/2014	29	44	N/A	63	N/A
3/31/2014	35	89	N/A	72	N/A
12/31/2013	34	87	N/A	47	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 2327の予測収益成長が貯蓄率 ( 2.3% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: 2327の収益がHong Kong市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: 2327の収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: 2327の収益がHong Kong市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: 2327の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 2327の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Meilleure Health International Industry Group 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Meilleure Health International Industry Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2023

Recent updates

Executive Co-Chairman of the Board recently bought HK$1.2m worth of stock

Executive Co-Chairman of the Board recently bought HK$245k worth of stock

Meilleure Health International Industry Group's (HKG:2327) Shareholders May Want To Dig Deeper Than Statutory Profit

First half 2024 earnings released: EPS: HK$0.002 (vs HK$0.004 in 1H 2023)

Now 21% undervalued

Executive Co-Chairman of the Board recently bought HK$432k worth of stock

New major risk - Revenue and earnings growth

Earnings Not Telling The Story For Meilleure Health International Industry Group Limited (HKG:2327) After Shares Rise 34%

Executive Co-Chairman of the Board recently bought HK$715k worth of stock

Meilleure Health International Industry Group (HKG:2327) Has A Somewhat Strained Balance Sheet

New minor risk - Share price stability

Meilleure Health International Industry Group Limited to Report First Half, 2024 Results on Aug 31, 2024

Meilleure Health International Industry Group Limited's (HKG:2327) 31% Share Price Plunge Could Signal Some Risk

Executive Co-Chairman of the Board recently bought HK$592k worth of stock

Meilleure Health International Industry Group (HKG:2327) Will Be Hoping To Turn Its Returns On Capital Around

Executive Co-Chairman of the Board recently bought HK$485k worth of stock

Optimistic Investors Push Meilleure Health International Industry Group Limited (HKG:2327) Shares Up 32% But Growth Is Lacking

Executive Co-Chairman of the Board recently bought HK$119k worth of stock

Meilleure Health International Industry Group Limited Announces Board and Committees Changes

Meilleure Health International Industry Group's (HKG:2327) Earnings Are Of Questionable Quality

Full year 2023 earnings released: EPS: HK$0.01 (vs HK$0.004 in FY 2022)

Dividend reduced to HK$0.004

Meilleure Health International Industry Group Limited, Annual General Meeting, Jun 27, 2024

Meilleure Health International Industry Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 20 August 2024

Meilleure Health International Industry Group Limited to Report Fiscal Year 2023 Final Results on Mar 28, 2024

Some Confidence Is Lacking In Meilleure Health International Industry Group Limited (HKG:2327) As Shares Slide 30%

Now 31% undervalued after recent price drop

Returns Are Gaining Momentum At Meilleure Health International Industry Group (HKG:2327)

Executive Co-Chairman of the Board recently bought HK$135k worth of stock

Executive Co-Chairman of the Board recently bought HK$133k worth of stock

Executive Co-Chairman of the Board recently bought HK$251k worth of stock

First half 2023 earnings released: EPS: HK$0.004 (vs HK$0.003 in 1H 2022)

New minor risk - Earnings quality

Returns At Meilleure Health International Industry Group (HKG:2327) Appear To Be Weighed Down

Meilleure Health International Industry Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2023

Meilleure Health International Industry Group Limited to Report First Half, 2023 Results on Aug 31, 2023

Upcoming dividend of HK$0.016 per share at 5.4% yield

Executive Co-Chairman of the Board recently bought HK$274k worth of stock

Meilleure Health International Industry Group Limited Approves Final Dividend

Executive Co-Chairman of the Board recently bought HK$153k worth of stock

Executive Co-Chairman of the Board recently bought HK$145k worth of stock

Full year 2022 earnings released: EPS: HK$0.004 (vs HK$0.014 in FY 2021)

Executive Co-Chairman of the Board recently bought HK$1.1m worth of stock

Executive Co-Chairman of the Board recently bought HK$272k worth of stock

Executive Co-Chairman of the Board recently bought HK$325k worth of stock

Less than half of directors are independent

Executive Co-Chairman of the Board recently bought HK$169k worth of stock

Investors Met With Slowing Returns on Capital At Meilleure Health International Industry Group (HKG:2327)

Now 22% undervalued after recent price drop

Now 21% undervalued after recent price drop

Is Meilleure Health International Industry Group (HKG:2327) A Risky Investment?

First half 2022 earnings released: EPS: HK$0.003 (vs HK$0.01 in 1H 2021)

Meilleure Health International Industry Group Limited to Report First Half, 2022 Results on Aug 26, 2022

Investors Will Want Meilleure Health International Industry Group's (HKG:2327) Growth In ROCE To Persist

Meilleure Health International Industry Group Limited, Annual General Meeting, Jun 24, 2022

Less than half of directors are independent

Executive Co-Chairman of the Board recently bought HK$305k worth of stock

Full year 2021 earnings released: EPS: HK$0.014 (vs HK$0.02 in FY 2020)

Executive Co-Chairman of the Board recently bought HK$1.1m worth of stock

Independent Non-Executive Director recently sold HK$142k worth of stock

Does Meilleure Health International Industry Group (HKG:2327) Have A Healthy Balance Sheet?

First half 2021 earnings released: EPS HK$0.01 (vs HK$0.01 in 1H 2020)

Executive Co-Chairman of the Board recently bought HK$1.7m worth of stock

Meilleure Health International Industry Group (HKG:2327) Shareholders Will Want The ROCE Trajectory To Continue

Full year 2020 earnings released: EPS HK$0.02 (vs HK$0.005 loss in FY 2019)

Meilleure Health International Industry Group (HKG:2327) Seems To Use Debt Rather Sparingly

Executive Co-Chairman of the Board recently bought HK$441k worth of stock

Full year 2020 earnings released: EPS HK$0.02 (vs HK$0.005 loss in FY 2019)

Meilleure Health International Industry Group Limited to Report Fiscal Year 2020 Results on Mar 19, 2021

New 90-day high: HK$0.69

Did You Miss Meilleure Health International Industry Group's (HKG:2327) Impressive 124% Share Price Gain?

New 90-day high: HK$0.57

Executive Co-Chairman of the Board recently bought HK$1.5m worth of stock

Executive Co-Chairman of the Board recently bought HK$1.4m worth of stock